Journal
NEPHROLOGIE & THERAPEUTIQUE
Volume 7, Issue 7, Pages 618-621Publisher
ELSEVIER MASSON
DOI: 10.1016/j.nephro.2011.11.008
Keywords
Belatacept; Bortezomide; Eculizumab; EBV vaccine; Renal transplantation; Pediatrics
Categories
Ask authors/readers for more resources
New immunosuppressive drugs are administered in adults after renal transplantation to prevent toxicities (nephrotoxicity, cardiovascular complications...). Among these, Belatacept exhibited exciting results and its indication in pediatric patients will have to be validated, especially in EBV-positive recipients. Rituximab, bortezomide and eculizumab are also currently being evaluated in protocols of desensitization and in the treatment of humoral rejections. An individually tailored immunosuppressive regimen might be considered in the future, based on the study of certain polymorphisms or on immune status and alloreactivity determined by new biomarkers. Finally, the development of EBV and cmV vaccines would prevent these infections after transplantation. (C) 2011 Association Societe de Nephrologie. Published by Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available